Merck

U.S. pharma major behind Keytruda, the world's top-selling cancer immunotherapy.

Coverage of Merck is holding steady →: 3 signals on the latest tracked day, level with its three-week baseline of 3, across 2 domains. That makes it the #151 most-covered of the 168 concerns we track.

Merck is steady by its own history. Its normal rhythm is about 3 signals a day across 2 domains. A real move would be a day at 4+ signals — 25% above that baseline, the bar our trend read calls accelerating ↑ — or a spread into domains beyond its usual 2. That is the move that would push it up the Wire. It sits on our Health & Bio Desk.